News for Agent

Daily business news: funding, M&A, launches

Leadership

Conexeu Sciences Appoints Daniel M. Bradbury Chairman as Jeff Sharpe Steps Down

By ·

Key takeaways

  • Daniel M. Bradbury becomes Chairman of Conexeu Sciences on December 1, 2026, succeeding Jeff Sharpe.
  • Bradbury spent 18 years at Amylin Pharmaceuticals and was its CEO from March 2007 until its $7 billion acquisition by Bristol-Myers Squibb in August 2012.
  • Conexeu plans a 510(k) submission in the first quarter of 2027 for its initial indication.

Conexeu Sciences Inc. appointed Daniel M. Bradbury as Chairman of its Board of Directors, effective December 1, 2026, succeeding Jeff Sharpe, who stepped down as Chairman and Director to make way for him. The company announced the move on November 19, 2026, according to GlobeNewswire.

Bradbury's Amylin and Equillium Tenure

Bradbury brings more than 40 years of experience. He was President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. from March 2007 until Bristol-Myers Squibb Company acquired it in August 2012 in a transaction valued at approximately $7 billion. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-weekly therapy to treat diabetes, and was listed on the Nasdaq 100. Before Amylin, he spent ten years in marketing and sales roles at SmithKline Beecham Pharmaceuticals.

Bradbury is Chairman and Co-Founder of Equillium, Inc., where he was Chief Executive Officer until January 2020 and Executive Chairman until October 2025, and led the company through its initial public offering. He chairs the board of Castle Biosciences, Inc. and is an independent director of Vivani Medical, Inc. and Biocon Limited. He is Managing Member of BioBrit, LLC, a life sciences consulting and investment firm based in La Jolla, California. In 2023, the Corporate Directors Forum named him Director of the Year for Lifetime Achievement in Corporate Governance.

Miles Harrison, Conexeu's President and Chief Executive Officer, credited Sharpe with guiding the company through its Nasdaq listing in May 2026. "We are delighted to welcome Dan as Chairman," Harrison said. "He has led a company from development through regulatory approval, commercial launch and a major acquisition, and has chaired the boards of public and private life sciences companies for more than a decade." Bradbury said he looked forward to working with Harrison and the management team "as Conexeu moves toward its first regulatory submission and commercial entry."

Board Expansion and Vancouver Laboratory

Conexeu expanded its board from six to nine directors on June 15, 2026, adding Ana Bastiani-Posner, April Burke and Andrew Costa as directors, promoting co-founder David Bogart to Chief Commercial Officer and adding Melinda Farina to its advisory board, according to akta.pro company records. The company opened a 30,000-square-foot research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, British Columbia, on June 23, 2026, as the operational hub for the CXU platform and B.R.E.A.S.T. program.

Funding Before the Chairmanship Change

Conexeu closed a $5 million private placement led by existing shareholders, management and directors in October 2026, according to GlobeNewswire. The placement included 1,666,667 units at $3.00 each, with $250,000 held in escrow pending stockholder approval. The company also announced in September 2026 that it would take part in three investor and industry conferences in September and October 2026, including the Nasdaq/LD Micro Summit, H.C. Wainwright's Global Investment Conference and Biotech on Tap, Stock Titan reported.

First-Quarter 2027 Submission Plan

Conexeu is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in the first calendar quarter of 2027 for its initial indication, subject to regulatory review.

Companies in this story

Sources

Machine-readable: Markdown · JSON